Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Depo-provera”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1978

Effect of injectable contraceptives Depo-Provera and norethisterone oenanthate on pituitary gonadotropin response to luteinizing hormone-releasing hormone.

The pituitary response to luteinizing hormone-releasing hormone (LHRH) was tested in women before and approximately 2, 8, and 12 weeks after the injection of either Depo-Provera or norethisterone oenanthate. The secretion of both luteinizing hormone and follicle-stimulating hormone in response to LHRH was similar in the two groups of women, and the pituitary was capable of responding to LHRH at all times studied after injection of the gestagens. There was no statistically significant difference between the response obtained prior to injection and that at any of the other time periods studied after injection.

Adult↗
PubMed1979

A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma.

A randomized study, comparing serum medroxyprogesterone concentrations by the oral and intramuscular routes, was performed on 22 patients with persistent or recurrent endometrial adenocarcinoma by six institutions of the Gynecologic Oncology Group. The oral group (11 patients) received cutaneous Provera (medroxyprogesterone), 50 mg three times a day, and the intramuscular group (11 patients) received 300 mg of Depo-Provera (medroxyprogesterone) weekly for at least 2 months. Serum levels were evaluated at 0, 2, 4, 6, 8, 10, and 12 hours after administration and every day for the first week and weekly thereafter for 8 weeks. The mean serum levels (nanograms per milliliter) of medroxyprogesterone in the oral group were consistently higher than the corresponding mean levels of the intramuscular group. In addition, from the first through eighth weeks, the measurements (medians) for the oral group were statistically higher than those for the intramuscular group. Although the study indicates a significant increase in serum levels achieved by the oral route, the follow-up period of patients under study is too early to evaluate its clinical effectiveness as compared to the intramuscular route.

Adenocarcinoma↗
PubMed1979

The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis.

In 26 women receiving either medroxyprogesterone acetate (Depo-Provera) injections or combined oestrogen-progestogen pills for contraception, tests of coagulation and fibrinolysis were performed before treatment, and after 8, 16 and 24 weeks of therapy. In the medroxyprogesterone group no significant changes were induced in fibrinogen, the vitamin K-dependent factors, or antithrombin III. Plasminogen levels fell during therapy, and were significantly lower than pre-treatment values after 16 and 24 weeks. By contrast, the 13 women receiving oral contraceptives showed raised levels of fibrinogen and plasminogen after 8 weeks of treatment, and of factors VII and X after 24 weeks. These data suggest that medroxyprogesterone acetate injections induce fewer changes in the blood coagulation system than oral contraceptives.

Adult↗
PubMed1978

Observations on family planning acceptors in Papua New Guinea.

The continuation contraceptive practise of 3,293 I.U.D., 1985 pill and 749 depo-provera acceptors was analysed by a survey of family planning records. The proportions of grand multiporae were 40.3%, 24.2% and 40.4% in the three groups. Pap smears were taken in from 12 to 38.5% of acceptors and the proportions of pathological smears varied from 8.9 to 13.3%. The percentages of acceptors who attended only once more were 11% (I.U.D.), 18.1% (pill) and 25.1% (d-p.), Pregnancy rates were for the I.U.D., 1.7 per Hundred Woman Years, for the 2.1 per H.W.Y. and for d-p, 0.4, per H.W.Y. Temporary interruptions of the contraceptive methods were common with the pill and d-p. In the long run the I.U.D. is superior to the other temporary methods of contraceptives. Continuation rates with the I.U.D. were 89.9% after one year and 70.9% after five years (similar rates for the pill were 55% and 16.5% and for d-p 50.5% and 10.3%). The importance of a proper pelvic examination and the need to have all methods available for any individual receiving contraceptives are emphasized in the discussion. Tubal ligations should always be considered as an alternative to the temporary methods of contraceptives in ground multiporae and others at special risk from further pregnancies.

Adult↗
PubMed1979

Toxicological barriers to providing better drugs.

The unmet needs of the sick demand that toxicologic requirements do not stifle the rational search for new and better remedies. A number of conceptual problems hamper the rational use of toxicological testing. These include: a misplaced confidence in the value of animal testing, a failure to make sophisticated risk-benefit analyses, the proliferation of new tests of uncertain validity, and improperly executed retrospective case control studies. Rugulatory barriers include the ever increasing bureaucratic demand for toxicological testing, the unseemly willingness of regulatory agencies to yield to hysterical or cynical consumer group pressures, the unreasonable demand for "superiority" of new products before the granting of registration, and the temptation to institute expensive but untested post-marketing surveillance schemes. Economic obstacles to new drug development have become formidable, and new demands for toxicologic studies in animals and humans are adding to these problems. Finally, some examples of unwise regulatory decisions involving saccharin, spray adhesives, Depo-Provera, and a new anti-metabolite are given.

Animals↗
PubMed1979

Interaction of estrogen and histamine during ovum implantation in the rat.

The relationship between estrogen and histamine in the initiation of ovum implantation in the rat was studied. Histamine was found to augment the implantation response to suboptimal doses of estradiol in the ovariectomized pregnant rat maintained with Depo-Provera. The effect of histamine was found to involve both H1- and H2-receptors and to be inhibited by treatment with a combination of mepyramine and metiamide. Treatment with this combination of histamine antagonists during early pregnancy in the intact rat did not modify blastocyst attachment. It was concluded that the effect of histamine on the implantation response to exogenous estradiol was due to increased uterine blood flow and/or estrogen uptake but that such histamine-mediated effects were not essential for blastocyst attachment during normal pregnancy.

Animals↗
PubMed1976

Steroidal compounds (injectable and implants) affecting spermatogenesis in men.

The effect of androgen and different progestins on spermatogenesis was studied in young men with subfertility, prostatovesiculitis and haematospermia, and in older men with benign hypertrophy of the prostate. The compounds (testosterone, testosterone oenanthate, ethinyl oestradiol, megestrol acetate, ethinyl norgestrienone and Depo-Provera) were administered intramuscularly, orally or as subcutaneous silastic implants.

Adult↗
PubMed1979

The protective influence of progestogen only contraception against vaginal moniliasis.

The incidence of Candida albicans (C.A.) infection of the vagina was evaluated in vaginal discharges obtained from 85 subjects using a large battery of culture media and confirmatory tests. Twenty women using DMPA 150 mg i.m. contraceptive injections for more than one year (long-term users) were compared with forty 2nd trimester pregnant cases with respect to vaginal candidiasis. The basis of comparison was the presence of amenorrhea and high hormonal levels in both groups. However, pregnant subjects showed a 60% prevalence while none of the DMPA cases had a positive culture or smear. Another group of 25 cases was similarly studied once before DMPA injection and again three months following drug administration (short-term use). The pre-therapy samples demonstrated a 32% incidence which was reduced to 8% after three months of use. It therefore appears that progestogen only contraceptives have the advantage of some protective influence against monilial vaginitis. Moreover, the use of these drugs may carry the beneficial potential of use in resistant cases of monilial vaginitis, either as a single approach or better as a supplementary procedure to known antifungal agents.

Adult↗
PubMed1979

Contraceptive use-effectiveness and the American adolescent.

Contraceptive use-effectiveness is significantly shaped by the contraceptors' ages, for pregnancy rates are found to be a function of age. Teenagers are more failure prone than older contracepting women, regardless of method. This higher teenage failure rate can indicate clearly the use-effectiveness of various contraceptive methods. Consequently, both user and method (whether modern or traditional) determine outcome levels of contraceptive use-effectiveness.

Abortion, Induced↗